MedTrace Logo

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

NCT02177305 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2014-06-27

No results posted yet for this study

Summary

Safety and tolerability after ocular administration

Conditions

  • Healthy

Interventions

DRUG

0.02 mcg tiotropium solution

DRUG

0.04 mcg tiotropium solution

DRUG

0.08 mcg tiotropium solution

DRUG

0.16 mcg tiotropium solution

DRUG

0.28 mcg tiotropium solution

DRUG

0.40 mcg tiotropium solution

DRUG

Placebo solution

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-10-31
Primary Completion
1998-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02177305 on ClinicalTrials.gov